Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

34.29 -33.40 (-49.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
These stocks are moving in today's after hours session
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Which stocks are moving on Monday?
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Gold Edges Higher; ISM Manufacturing PMI Falls In October
 
Via Benzinga
uniQure Stock Tumbled 56% Today: What’s The FDA Angle?
Via Stocktwits
UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data
UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans. 
Via Benzinga
Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Gapping stocks in Monday's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE
From The DJS Law Group
Via Business Wire
Nasdaq Surges 1%; ON Semiconductor Posts Upbeat Q3 Earnings
 
Via Benzinga
Uniqure Plummets 59% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy
An analyst described the FDA feedback as "confusing" and "unexpected" for the experimental Huntington's disease treatment. 
Via Investor's Business Daily
Discover the top movers in Monday's pre-market session.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Breakout Momentum Plays You Need to Know About
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential. 
Via MarketBeat
Why Is Protalix BioTherapeutics Stock Falling On Friday?
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy. 
Via Benzinga
Cramer Warns On One Chip Stock, Says Broadcom Is The Better Bet
Jim Cramer recommends caution with Ambiq Micro (AMBQ) and suggests Broadcom (AVGO). He dislikes Albertsons (ACI) and advises selling some Dillard's (DDS). 
Via Benzinga
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop
Biotech stock uniQure just popped nearly 250% in one day, with an analyst calling its trial results "amazing". Wall Street sees significant upside to come. 
Via MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
From uniQure Inc.
Via GlobeNewswire
Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slide
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
uniQure Announces Pricing of Upsized $300 Million Public Offering
From uniQure Inc.
Via GlobeNewswire
UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street
UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease... 
Via Benzinga
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
uniQure Stock Jumps On Positive News, But Risks Remain
uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in... 
Via Benzinga
Wall Street Pauses AI Frenzy as Oracle Seeks $15B in Fresh Funding
After weeks of record highs fueled by AI optimism, U.S. stocks cooled for a second straight day. Oracle’s massive debt raise and divergent moves in chipmakers set the tone, while housing and lithium... 
Via Chartmill
Topics Artificial Intelligence
Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85. 
Via Benzinga
UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’
UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.